Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
CMF compared to CAF with and without tamoxifen in node-negative breast cancer
February 9th, 2006
Cyclophosphamide, methotrexate, and fluorouracil (CMF) was compared to cyclophosphamide, doxorubicin, and fluorouracil (CAF) with and without tamoxifen (TAM). According to recent research from the United States, "We evaluated the efficacy of CMF versus CAF in node-negative breast cancer patients with and without TAM, overall and by hormone receptor (HR) status. Node-negative patients identified by tumor size (>2 cm), negative HR, or high S-phase fraction (n=2,690) were randomly assigned to CMF, CAF, CMF + TAM (CMFT), or CAF + TAM (CAFT). Cox regression evaluated overall survival (OS) and disease-free survival (DFS) for CAF versus CMF and TAM versus no TAM...
Source: Women's Health Weekly (2006-02-09)
|
